CL2019002155A1 - Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas. - Google Patents
Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas.Info
- Publication number
- CL2019002155A1 CL2019002155A1 CL2019002155A CL2019002155A CL2019002155A1 CL 2019002155 A1 CL2019002155 A1 CL 2019002155A1 CL 2019002155 A CL2019002155 A CL 2019002155A CL 2019002155 A CL2019002155 A CL 2019002155A CL 2019002155 A1 CL2019002155 A1 CL 2019002155A1
- Authority
- CL
- Chile
- Prior art keywords
- fusion proteins
- factor
- procedures
- preparation
- fix
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
LA PRESENTE DESCRIPCIÓN PROPORCIONA PROTEÍNAS DE FUSIÓN DEL FACTOR IX (FIX) QUE COMPRENDEN AL MENOS UN RESTO HETERÓLOGO, TAL COMO UN XTEN. LA PRESENTE DESCRIPCIÓN DESCRIBE ADEMÁS MÉTODOS PARA PREPARAR Y UTILIZAR LAS PROTEÍNAS DE FUSIÓN DEL FIX.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762452826P | 2017-01-31 | 2017-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019002155A1 true CL2019002155A1 (es) | 2020-02-21 |
Family
ID=61193175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019002155A CL2019002155A1 (es) | 2017-01-31 | 2019-07-31 | Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas. |
Country Status (19)
Country | Link |
---|---|
US (1) | US20210238259A1 (es) |
EP (1) | EP3576762A1 (es) |
JP (1) | JP2020505424A (es) |
KR (1) | KR20190112763A (es) |
CN (1) | CN110831613A (es) |
AR (1) | AR110871A1 (es) |
AU (1) | AU2018215092A1 (es) |
BR (1) | BR112019015569A2 (es) |
CA (1) | CA3051862A1 (es) |
CL (1) | CL2019002155A1 (es) |
CR (1) | CR20190389A (es) |
EA (1) | EA201991768A1 (es) |
IL (1) | IL268234A (es) |
MA (1) | MA47416A (es) |
MX (1) | MX2019009063A (es) |
PH (1) | PH12019501765A1 (es) |
SG (1) | SG11201906788XA (es) |
TW (1) | TW201831521A (es) |
WO (1) | WO2018144623A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112175088B (zh) * | 2019-07-02 | 2023-03-28 | 江苏晟斯生物制药有限公司 | 改进的fix融合蛋白、缀合物及其应用 |
CN113817759B (zh) * | 2020-07-10 | 2023-06-02 | 南京吉迈生物技术有限公司 | 修饰的因子ix、组合物、方法及其在基因治疗中的应用 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
DE3684546D1 (de) | 1985-04-22 | 1992-04-30 | Genetics Inst | Herstellung mit hoher leistung des aktivfaktors ix. |
EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
DK0461200T3 (da) | 1989-02-21 | 1997-03-10 | Univ Washington | Modificerede former af reproduktionshormoner |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
WO1992016221A1 (en) | 1991-03-15 | 1992-10-01 | Synergen, Inc. | Pegylation of polypeptides |
US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
DE69332859T2 (de) | 1992-11-13 | 2003-12-18 | Idec Pharmaceuticals Corp., San Diego | Konsensus-kozak-sequenzen zur säugetier-exprimierung |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
PT981637E (pt) | 1997-03-14 | 2005-09-30 | Biogen Idec Inc | Metodo para integrar genes em sitios especificos em celulas de mamifero atraves de recombinacao homologa e vectores para a realizacao do mesmo |
EP1276756A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
WO2002040544A2 (en) | 2000-11-14 | 2002-05-23 | Board Of Regents, University Of Texas Systems | Mutant human factor ix with an increased resistance to inhibition by heparin |
WO2003020764A2 (en) | 2001-09-04 | 2003-03-13 | Merck Patent Gmbh | Modified factor ix |
KR101271635B1 (ko) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
KR101654011B1 (ko) | 2004-11-12 | 2016-09-05 | 바이엘 헬스케어 엘엘씨 | Fviii의 부위 지향 변형 |
AU2006280312A1 (en) | 2005-08-12 | 2007-02-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
EP2084274A2 (en) | 2006-06-19 | 2009-08-05 | Nautilus Technology LLC | Modified coagulation factor ix polypeptides and use thereof for treatment |
JP2010503396A (ja) | 2006-09-14 | 2010-02-04 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | アルブミン融合タンパク質 |
US7700734B2 (en) | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
DE602008005596D1 (de) | 2007-06-21 | 2011-04-28 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
JP5613876B2 (ja) | 2007-10-15 | 2014-10-29 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 延長された半減期を備えるヒト第ix因子変異体 |
CN102083856A (zh) | 2008-04-16 | 2011-06-01 | 拜耳医药保健有限公司 | 经修饰的因子ix多肽及其用途 |
CN102065887A (zh) | 2008-04-16 | 2011-05-18 | 拜耳医药保健有限公司 | 因子ix的定点修饰 |
AR071478A1 (es) | 2008-04-17 | 2010-06-23 | Baxter Healthcare Sa | Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi |
EP2268807A2 (en) | 2008-04-21 | 2011-01-05 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
WO2010091122A1 (en) | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
AU2010258898B8 (en) | 2009-06-08 | 2015-02-05 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
EA030619B1 (ru) | 2009-06-08 | 2018-09-28 | Амуникс Оперейтинг Инк. | Гибридный белок, включающий последовательности гормона роста и xten, способ его получения и применения |
US20120263701A1 (en) | 2009-08-24 | 2012-10-18 | Volker Schellenberger | Coagulation factor vii compositions and methods of making and using same |
WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
HUE036233T2 (hu) | 2009-12-06 | 2018-06-28 | Bioverativ Therapeutics Inc | VIII-FC Faktor kimérás és hibrid polipeptidek, és ezek használati módszerei |
UA115120C2 (uk) | 2010-07-09 | 2017-09-25 | Байоджен Хемофіліа Інк. | Спосіб застосування химерного поліпептиду фактора ix |
KR20140002601A (ko) | 2010-07-09 | 2014-01-08 | 바이오겐 이데크 헤모필리아 인코포레이티드 | 키메라 응고 인자 |
EP3508573A1 (en) | 2010-07-09 | 2019-07-10 | Bioverativ Therapeutics Inc. | Systems for factor viii processing and methods thereof |
PT2882450T (pt) | 2012-07-11 | 2020-02-19 | Bioverativ Therapeutics Inc | Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo |
EP3033097B1 (en) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Factor viii-xten fusions and uses thereof |
AU2016301303B2 (en) * | 2015-08-03 | 2021-10-07 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
-
2018
- 2018-01-31 TW TW107103461A patent/TW201831521A/zh unknown
- 2018-01-31 US US16/478,747 patent/US20210238259A1/en not_active Abandoned
- 2018-01-31 EP EP18704801.2A patent/EP3576762A1/en not_active Ceased
- 2018-01-31 MA MA047416A patent/MA47416A/fr unknown
- 2018-01-31 CR CR20190389A patent/CR20190389A/es unknown
- 2018-01-31 CA CA3051862A patent/CA3051862A1/en active Pending
- 2018-01-31 KR KR1020197025194A patent/KR20190112763A/ko not_active Application Discontinuation
- 2018-01-31 MX MX2019009063A patent/MX2019009063A/es unknown
- 2018-01-31 JP JP2019541361A patent/JP2020505424A/ja active Pending
- 2018-01-31 WO PCT/US2018/016277 patent/WO2018144623A1/en unknown
- 2018-01-31 CN CN201880020779.XA patent/CN110831613A/zh active Pending
- 2018-01-31 AU AU2018215092A patent/AU2018215092A1/en active Pending
- 2018-01-31 BR BR112019015569-4A patent/BR112019015569A2/pt unknown
- 2018-01-31 SG SG11201906788XA patent/SG11201906788XA/en unknown
- 2018-01-31 EA EA201991768A patent/EA201991768A1/ru unknown
- 2018-01-31 AR ARP180100235A patent/AR110871A1/es unknown
-
2019
- 2019-07-23 IL IL268234A patent/IL268234A/en unknown
- 2019-07-30 PH PH12019501765A patent/PH12019501765A1/en unknown
- 2019-07-31 CL CL2019002155A patent/CL2019002155A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018144623A1 (en) | 2018-08-09 |
AU2018215092A1 (en) | 2019-08-29 |
JP2020505424A (ja) | 2020-02-20 |
MX2019009063A (es) | 2019-10-21 |
MA47416A (fr) | 2019-12-11 |
KR20190112763A (ko) | 2019-10-07 |
AR110871A1 (es) | 2019-05-08 |
IL268234A (en) | 2019-09-26 |
TW201831521A (zh) | 2018-09-01 |
SG11201906788XA (en) | 2019-08-27 |
CA3051862A1 (en) | 2018-08-09 |
CN110831613A (zh) | 2020-02-21 |
BR112019015569A2 (pt) | 2020-03-17 |
EA201991768A1 (ru) | 2020-01-22 |
PH12019501765A1 (en) | 2020-03-16 |
US20210238259A1 (en) | 2021-08-05 |
CR20190389A (es) | 2019-11-26 |
EP3576762A1 (en) | 2019-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018000302A1 (es) | Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas | |
CO2020006900A2 (es) | Medios y método para preparar vectores virales y usos de los mismos | |
CO2019003154A2 (es) | Anticuerpos anti-pd-1 y sus usos | |
CO2018005369A2 (es) | Inhibidores triazol de acc y usos de los mismos | |
BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
CL2018000358A1 (es) | Proteínas de fusión de gitrl y usos de las mismas | |
BR112017003414A2 (pt) | composições compreendendo caseína e métodos para produzir as mesmas | |
MX2019007021A (es) | Anticuerpos il-11ra. | |
CR20160141A (es) | Formulaciones de anticuerpos anti-pdl1 | |
CO2018012699A2 (es) | Anticuerpos anti-cd40 y sus usos | |
CR20150482A (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
BR112017009374A2 (pt) | ?composições de ramnolipídeo de baixa viscosidade concentradas? | |
SG10201809628SA (en) | Anti-ptk7 antibody-drug conjugates | |
UY34617A (es) | Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas | |
BR112017025711A2 (pt) | ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras? | |
CL2019002251A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. | |
BR112018001814A2 (pt) | unidade móvel de produção de implante | |
CY1122644T1 (el) | Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων | |
BR112017009792A2 (pt) | anticorpos anti-pdgf-b e métodos de uso | |
UY35463A (es) | Formulaciones de polipéptido fc-factor ix. | |
BR112017014598A2 (pt) | métodos e usos para hidrólise de queratina | |
CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
CL2019002155A1 (es) | Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas. | |
MX2017009180A (es) | Biomateriales de nanocelulosa sintetizada bacterialmente y de fases múltiples, y método para producirlos. | |
BR112018077458A2 (pt) | proteases aspárticas |